Blueprint Medicines (BPMC) Reports In-Line Q2 EPS

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($1.86), in-line with the analyst estimate of ($1.86). Revenue for the quarter came in at $27.3 million versus the consensus estimate of $19.01 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight